Human Engineered Anti-Autoimmune-Disease Regulatory T Cells System
Abstract
FOXP3+ regulatory T cells (Treg) are a class of T lymphocyte subsets that play an immunosuppressive and regulatory function.
The dysfunction of FOXP3+ Treg is closely related to the development of autoimmune diseases, say rheumatoid arthritis. FOXP3,
a transcription factor in Forkhead family, whose functional stability is regulated by post-translational modification enzymes, is a
key transcription factor for Treg cells' specific expression. The ubiquitinase USP7 was able to specifically modify the FOXP3
protein by specific ubiquitination to enhance the functional stability of FOXP3, thereby enhancing the immunosuppressive function
of Treg cells.
In patients with rheumatoid arthritis, the balance between Th17 and Treg is usually broken, and inflammatory cells like Th17
predominate in the human body. A quantity of inflammatory cytokines, such as IL-17A, IL-6 and TNF-α and so on, secreted by Th17 and
other inflammatory cells enhance the inflammation of the lesion, which causes the local enrichment of effector cells such as CD20+
B lymphocytes in the focus and deprives the normal function of Treg cells, resulting in further decline in immunosuppressive
capacity. Based on these facts, we hope that our cell therapy program that is to isolate and obtain primary regulatory T cells from
rheumatoid arthritis patients and then infute engineered Treg cells again to the human body, can have a promising effect in the
treatment of rheumatism.
In our design, first, we designed a SynNotch system that contains a modified Notch protein capable of specifically activating the gene expression of USP7 in inflammatory conditions with the presence of IL17A. USP7 proteins can lead to de-ubiquitination of the FOXP3 protein, so that it can enhance the stability of FOXP3 protein in the inflammation environment by protecting FOXP3 from degradation via ubiquitination. As a result, Treg cells can maintain their immunosuppressive function. Meantime, we designed a CAR system that enables
Treg cells to target CD20+ B lymph Cell specifically to play an immunosuppressive function and thus take an anti-inflammatory effect.
Given our design and purpose, we call the system a Human Engineered Anti-Autoimmune Disease Regulatory T Cells System (HEAD-Treg).
Introduction and Background
People are exposed to billions of pathogens every day. In the meantime, billions of cells within our body undergo a complicated process
from generation, aging to apoptosis, together with injuries and mutations. Our immune system identifies and eliminates the threat from inside and outside of our body with precision and efficacy, just like an elaborated network.
In accordance with the Chinese Yin-Yang theory and the western critical thinking, our immune system is under a dynamic equilibrium
at all times. The immune network consisting of immune organs, immune tissues and immune cells rely on each other and promote each other,
which is a both unified and varying state which called as immune homeostasis, with immune response and immune tolerance as two most
critical features. On one hand, immune response helps us get rid of antigens, and eradicate harmful factors against human body; on
the other hand, immune tolerance helps us distinguishing the enemies from our own, avoiding any harm from overreaction and indiscriminate
destruction. Thus, the immune homeostasis is a prerequisite for our healthy life, once the balance is no longer maintained a series of
diseases will occur and physical functions may fail. If immune tolerance shows more potency than immune response, the human body will be
in an immune inhibited state, where pathogens and cancer cells are left uncontrolled leading to the onset of severe infection and malignancy.
If immune response gains the upper hand over immune tolerance, normal cells will be targeted for elimination leading to diseases we call as
autoimmune diseases, for example rheumatoid arthritis(RA), systematic lupus erythromatosis, autoimmune type I diabetes, etc. In this way,
finding a way to recover the immune homeostasis becomes an essential strategy in dealing with these two types of diseases.
An imbalance in immune cell’s function is often found in them. Sometime the immune system cannot recognize the target cell, sometime a
certain type of immune cell may proliferate. Thus, remodeling the function of a crucial type of immune cell turns into a key point.
Cytotherapy has, therefore, become a rising star against these diseases, with CAR-T and TCR-T as the representatives in this technology.
The trick in these therapies lies in transforming T cells with synthetic biology approaches, inserting and expressing artificial genes of
chimeric antigen receptor into T cell genome and enabling them to recognize and eradicate target cells precisely. Obviously, such strategy
has achieved a certain success. This year, the CAR-T product from Novartis was officially approved by FDA to treat acute lymphoblastic
leukemia(ALL) in enfants and young adults, which has shown high efficacy in the treatment of non-solid tumors.
Two subtypes of immune cells are of great significance with respect to the onset of autoimmune diseases like RA, one is the incendiary
of inflammation which is called Th17 cell, and one is the firefighter of inflammation which is called regulatory T cell(Treg). In normal
human body, the ratio of Th17 to Treg is in a dynamic equilibrium, while in rheumatoid arthritis patients Th17 greatly outnumbers Treg in
the focus of a lesion. Inflammatory cytokines secreted by Th17, including IL-17, IL-6, TNF-α, will trigger a cascade of reaction causing
severe inflammation locally together with B lymphocytes which may further lead to organ dysfunction and could be fatal.
Figure1. The dynamic balance and mutual transformation between Regulatory T cells and Th17 cells
FOXP3 is the most important transcription factor in Treg, taking part in most of the transcription and expression of Treg structural
genes. We can assume that the expression and stability of FOXP3 protein determines the function level of Treg. Under inflammation environment,
a series of cytokines, such as IL-6, will activate a ubiquitinase Stub1 which will ubiquitinate FOXP3, thus leading to its deactivation and
degradation. Consequently, Treg loses its immune inhibitory function, which is mainly why Treg cannot function properly in RA patients. In
this way, how to engineer Treg cell to maintain its FOXP3 stability under inflammation conditions and how to direct Treg to target RA specific
inflammatory cells to exert its immune inhibitory function becomes a new strategy against RA.
Mathematical Model Analysis
In different tissues, the proportion of different types of CD4+ lymphocytes, to a large extent, is determined by various
cytokines that can induce the differentiation of CD4+ CD45RA+ naive T cells. For example, IL-12 leads to Th1 cells, Il-4 leads
to Th2 cells and TGF-β leads to Treg cells. Many studies have also shown that subgroups of helper T cells such as Th1, Th2,
Th17, and Treg, which have been differentiated into functional subpopulations, can also be transdifferentiated into other
subgroups of helper T cells under the action of certain cytokines. Their original functions may decline if transdifferentiation
does not happen in some conditions.
In order to theoretically demonstrate that regulatory T cells are dysfunctional or transdifferentiated in the cell
microenvironment of rheumatoid arthritis patients imbued with a large number of inflammatory factors, and to describe the
necessity of intervening the corresponding regulatory pathway of Treg cells in the clinical treatment of rheumatoid arthritis,
we established the mathematical model of T cell differentiation and transdifferentiation (see more from Model section).
Based on our mathematical model analysis, we can theoretically come to the conclusion that in patients with rheumatoid
arthritis, due to the secretion of inflammatory cytokines, the T cell differentiation to functional effector T cells will
be promoted and meanwhile the function of regulatory T cells will be further weakened. We can also learn that regulatory T
cells cannot survive in too intensive inflammatory environment in the bodies of rheumatoid arthritis patients. In the light
of all conclusions of the mathematical model analysis, our design ideas for the treatment of rheumatoid arthritis has become
clearer: enhance the stability of regulatory T cells in the presence of inflammatory cytokines by inserting our new system,
thereby blocking inflammation the occurrence of dysfunction and transdifferentiation of Treg cells. Finally, we established
the following intervention strategy (Figure 2).
Figure2. The ubiquitination mechanism of FOXP3 in regulatory T cells
under inflammatory conditions and our intervention strategy
SynNotch System
In order to deal with RA, we need to arm Treg with a sharp spear as well as a solid shield. With no doubt, a solid shield is the premise
of survival in a difficult situation. That is why we try to activate a pathway to protect FOXP3 under inflammatory conditions in our design.
We choose to focus on USP7, a protein that can promote FOXP3 stability by deubiquitinating FOXP3 specifically. An up-regulation in USP7
expression can result in an enhanced immune inhibitory function of Treg. Thus, we decide to express a SynNotch system in Treg, which can
specifically activate the transcription of USP7 after receiving an inflammatory stimulus.
SynNotch, as you can tell from its name, is a synthetic biologically engineered Notch protein. Notch protein is a transmembrane protein,
which can be divided into three domains: extracellular domain, transmembrane domain and intracellular domain. There is a cleavage site within
its intracellular domain at which the Notch protein will be cleaved under stimulus, releasing its C-terminal peptide from the membrane to
bind with a downstream protein and carrying out the signal transduction. Apparently, this is a non-specific signal transduction system. In
our SynNotch system, we retain the transmembrane domain as well as its cleavage site, while on the N-terminal we fuse the extracellular domain
of IL-17AR with Notch1 so that it can specifically recognize IL-17A, a cytokine secreted by Th17. In this way, our Treg is capable of sensing
the presence of IL-17A. The next question is how to enable the protein cleaved by SynNotch to recognize and activate the transcription of USP7.
That is where we introduce our next system, the Gal4-UAS system in yeast.
In yeast cells, Gal4 protein can specifically recognize the UAS sequence in its genome. If we attach an artificial transcription
factor VP64 to Gal4 and insert UAS sequence before the promoter of target gene, we can presume that the transcription of target gene
will be specifically activated. Thus, we add a Gal4-VP64 fusion protein sequence after the cleavage site in SynNotch system, meanwhile
we add the UAS sequence before USP7 promoter. Now with the presence of the inflammatory cytokine IL-17A, SynNotch system will be
activated and the cleavage will take place. Gal4-VP64 will be freed from cell membrane before entering the cell nucleus and binding
with the UAS sequence before USP7 promoter. Then USP7 protein will be expressed and will deubiquitinate FOXP3, stabilizing FOXP3 under
inflammation conditions, making it possible for Treg to survive the inflammatory environment and to exert its immune inhibitory function.
Above is the shield we equip Treg with.
Figure3. Design of SynNotch system and CAR system
CAR System
Next, we design a sharp spear for Treg. We choose the B lymphocyte with CD20 high expression as our target for Treg, so we introduce
a CAR system into Treg to let it specifically recognize the CD20 antigen at the surface of B lymphocytes in order to achieve anti-inflammatory
function. As for the design of our CAR system, we use the scFv fragment of CD20 monoclonal antibody as the extracellular fraction because
it can recognize and bind with CD20 on B lymphocyte’s surface accurately. We then choose a CD3Z sequence as the stimulatory signal and two
4-1-BB sequences as the co-stimulatory signal to make sure the signal can be delivered into the cell at a high level, thus activating an
effective response of Treg. We attach a red fluorescent protein mCherry to the end of the CAR fusion protein as a report signal for a more
convenient detection. By designing this CAR system we equip our Treg with a spear, which can reduce the inflammation level in RA patients.
Based on our design, we name our engineered Treg as “Human Engineered Anti-Autoimmune-Disease Regulatory T cell (HEAD-Treg) System”.
We hope it can serve as a mighty warrior, leading the immune system to rebalance itself, to conquer the disease and to reestablish the
patient’s health.
Figure4. HEAD-Treg System
Summary and Prospect
Undeniably, there are no effective clinical methods against autoimmune diseases such as RA. The drugs we use clinically including
glucocorticoids, chemical agents and monoclonal antibodies are all flawed in one way or another. It is definitely a tough war on how to
reconstitute the homeostasis in patients with autoimmune diseases.
Based on our strategy, the stabilization of the function of Treg as well as the equipment of a targeted inhibition are the two key
points in treating RA, with the SynNotch system as its core. While we focus on RA as our purpose, we are also trying to develop our
SynNotch system into a universal component to carry out specific activation(Gal4-VP64) or inhibition(Gal4-Krab) of target gene under
particular signal stimulus in mammal cells. We hope to discover its potential application value in treating cancer, diabetes and inducing
the differentiation of stem cells.
Exploring and applying an effective therapeutic approach towards RA, a typical autoimmune disease, is something truly meaningful.
Our attempt is also an understanding and interpretation of synthetic biology. We do believe that synthetic biology techniques will play
a more and more critical role in future cytotherapy, and even the treatment of a series of human diseases.
Reference:
1. Roybal KT, Williams JZ, et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic
Notch Receptors. Cell 2016. doi: 10.1016/j.cell.2016.09.011.
2. Klebanoff CA, Restifo NP. Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells. Cell
2016. doi: 10.1016/j.cell.2016.09.033.
3. Ellebrecht CT, Bhoj VG, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune
disease. Science 2016. doi: 10.1126/science.aaf6756.
4. Fransson M, Piras E, et al. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal
delivery. J Neuroinflammation. 2012. doi: 10.1186/1742-2094-9-112.
5. MacDonald KG, Hoeppli RE, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.
J Clin Invest. 2016. doi: 10.1172/JCI82771. Epub 2016 Mar 21.
6. Roybal KT, Rupp LJ. et al. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.
Cell. 2016. doi: 10.1016/j.cell.2016.01.011.
7. Kononenko AV, Lee NC. et al. Generation of a conditionally self-eliminating HAC gene delivery vector through incorporation
of a tTAVP64 expression cassette. Nucleic Acids Res. 2015. doi: 10.1093/nar/gkv124.
8. Müller K, Zurbriggen MD, Weber W. An optogenetic upgrade for the Tet-OFF system. Biotechnol Bioeng. 2015. doi:
10.1002/bit.25562.
9. Khalil DN, Smith EL, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
Nat Rev Clin Oncol. 2016 May. doi: 10.1038/nrclinonc.2016.25.
10. Chen Z, Barbi J, et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity
by promoting degradation of the transcription factor Foxp3. Immunity. 2013. doi: 10.1016/j.immuni.2013.08.006.
11. Van Loosdregt J, Fleskens V, et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7
increases Treg-cell-suppressive capacity. Immunity. 2013. doi: 10.1016/j.immuni.2013.05.018.
12. Wang L, Kumar S, et al. Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory
Cell Function and Promotes Antitumor Immunity. EBioMedicine. 2016. doi: 10.1016/j.ebiom.2016.10.018.
13. Wang L, Kumar S, Dahiya S,et al. Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory
Cell Function and Promotes Antitumor Immunity. EBioMedicine. 2016 Nov;13:99-112. doi: 10.1016/j.ebiom.2016.10.018.
14. Ren J, Li B. The Functional Stability of FOXP3 and RORγt in Treg and Th17 and Their Therapeutic Applications.
Adv Protein Chem Struct Biol. 2017;107:155-189. doi: 10.1016/ bs.apcsb.2016.10.002. Epub 2016 Dec 15.
15. Chen X, Oppenheim JJ. Th17 cells and Tregs: unlikely allies. J Leukoc Biol. 2014 May;95(5):723-731. Epub 2014
Feb 21.